Literature DB >> 28559332

Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.

Kohta Saito1,2, Thulasi Warrier1, Selin Somersan-Karakaya2, Lina Kaminski3, Jianjie Mi1, Xiuju Jiang1, Suna Park1, Kristi Shigyo1, Ben Gold1, Julia Roberts1, Elaina Weber1, William R Jacobs3,4, Carl F Nathan5.   

Abstract

Mycobacterium tuberculosis (Mtb) encounters stresses during the pathogenesis and treatment of tuberculosis (TB) that can suppress replication of the bacteria and render them phenotypically tolerant to most available drugs. Where studied, the majority of Mtb in the sputum of most untreated subjects with active TB have been found to be nonreplicating by the criterion that they do not grow as colony-forming units (cfus) when plated on agar. However, these cells are viable because they grow when diluted in liquid media. A method for generating such "differentially detectable" (DD) Mtb in vitro would aid studies of the biology and drug susceptibility of this population, but lack of independent confirmation of reported methods has contributed to skepticism about their existence. Here, we identified confounding artifacts that, when avoided, allowed development of a reliable method of producing cultures of ≥90% DD Mtb in starved cells. We then characterized several drugs according to whether they contribute to the generation of DD Mtb or kill them. Of the agents tested, rifamycins led to DD Mtb generation, an effect lacking in a rifampin-resistant strain with a mutation in rpoB, which encodes the canonical rifampin target, the β subunit of RNA polymerase. In contrast, thioridazine did not generate DD Mtb from starved cells but killed those generated by rifampin.

Entities:  

Keywords:  Mycobacterium tuberculosis; differentially detectable; phenotypic tolerance; rifampin; thioridazine

Mesh:

Substances:

Year:  2017        PMID: 28559332      PMCID: PMC5474769          DOI: 10.1073/pnas.1705385114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

Review 1.  New insights into the function of granulomas in human tuberculosis.

Authors:  Timo Ulrichs; Stefan H E Kaufmann
Journal:  J Pathol       Date:  2006-01       Impact factor: 7.996

Review 2.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

3.  Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide.

Authors:  Y Hu; J A Mangan; J Dhillon; K M Sole; D A Mitchison; P D Butcher; A R Coates
Journal:  J Bacteriol       Date:  2000-11       Impact factor: 3.490

4.  Mycobacterium tuberculosis can utilize heme as an iron source.

Authors:  Christopher M Jones; Michael Niederweis
Journal:  J Bacteriol       Date:  2011-02-04       Impact factor: 3.490

5.  Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.

Authors:  Noton K Dutta; Michael L Pinn; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

6.  Differential influence of nutrient-starved Mycobacterium tuberculosis on adaptive immunity results in progressive tuberculosis disease and pathology.

Authors:  Jes Dietrich; Sugata Roy; Ida Rosenkrands; Thomas Lindenstrøm; Jonathan Filskov; Erik Michael Rasmussen; Joseph Cassidy; Peter Andersen
Journal:  Infect Immun       Date:  2015-09-28       Impact factor: 3.441

7.  Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.

Authors:  Sekai Chideya; Carla A Winston; Charles A Peloquin; William Z Bradford; Philip C Hopewell; Charles D Wells; Arthur L Reingold; Thomas A Kenyon; Themba L Moeti; Jordan W Tappero
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

8.  Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis.

Authors:  Kristina Shigyo; Oksana Ocheretina; Yves Mary Merveille; Warren D Johnson; Jean William Pape; Carl F Nathan; Daniel W Fitzgerald
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

9.  Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis.

Authors:  Melissa D Chengalroyen; Germar M Beukes; Bhavna G Gordhan; Elizabeth M Streicher; Gavin Churchyard; Richard Hafner; Robin Warren; Kennedy Otwombe; Neil Martinson; Bavesh D Kana
Journal:  Am J Respir Crit Care Med       Date:  2016-12-15       Impact factor: 21.405

Review 10.  Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action.

Authors:  Leonard Amaral; Miguel Viveiros
Journal:  Antibiotics (Basel)       Date:  2017-01-14
View more
  30 in total

1.  Differentially Culturable Tubercule Bacilli Are Generated during Nonpulmonary Tuberculosis Infection.

Authors:  Andrew Rosser; Manish Pareek; Obolbek Turapov; Martin J Wiselka; Galina V Mukamolova
Journal:  Am J Respir Crit Care Med       Date:  2018-03-15       Impact factor: 21.405

Review 2.  Biology of antimicrobial resistance and approaches to combat it.

Authors:  Sarah M Schrader; Julien Vaubourgeix; Carl Nathan
Journal:  Sci Transl Med       Date:  2020-06-24       Impact factor: 17.956

3.  Molecular Bacterial Load Assay Concurs with Culture on NaOH-Induced Loss of Mycobacterium tuberculosis Viability.

Authors:  Bariki Mtafya; Wilber Sabiiti; Issa Sabi; Joseph John; Emanuel Sichone; Nyanda E Ntinginya; Stephen H Gillespie
Journal:  J Clin Microbiol       Date:  2019-06-25       Impact factor: 5.948

4.  Synthesis and Evaluation of Marine Natural Product-Inspired Meroterpenoids with Selective Activity toward Dormant Mycobacterium tuberculosis.

Authors:  Anshupriya Si; Alexander D Landgraf; Sandra Geden; Steven J Sucheck; Kyle H Rohde
Journal:  ACS Omega       Date:  2022-06-27

Review 5.  Mechanisms of Drug-Induced Tolerance in Mycobacterium tuberculosis.

Authors:  Sander N Goossens; Samantha L Sampson; Annelies Van Rie
Journal:  Clin Microbiol Rev       Date:  2020-10-14       Impact factor: 26.132

6.  A Multistress Model for High Throughput Screening Against Nonreplicating Mycobacterium tuberculosis.

Authors:  Ben Gold; Thulasi Warrier; Carl Nathan
Journal:  Methods Mol Biol       Date:  2021

Review 7.  Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development.

Authors:  Lloyd Tanner; Paolo Denti; Lubbe Wiesner; Digby F Warner
Journal:  IUBMB Life       Date:  2018-06-22       Impact factor: 3.885

Review 8.  Heterogeneous Host-Pathogen Encounters Coordinate Antibiotic Resilience in Mycobacterium tuberculosis.

Authors:  Richa Mishra; Vikas Yadav; Madhura Guha; Amit Singh
Journal:  Trends Microbiol       Date:  2020-12-10       Impact factor: 17.079

9.  Genetic models of latent tuberculosis in mice reveal differential influence of adaptive immunity.

Authors:  Hongwei Su; Kan Lin; Divya Tiwari; Claire Healy; Carolina Trujillo; Yao Liu; Thomas R Ioerger; Dirk Schnappinger; Sabine Ehrt
Journal:  J Exp Med       Date:  2021-07-16       Impact factor: 14.307

10.  Characterization of Differentially Detectable Mycobacterium tuberculosis in the Sputum of Subjects with Drug-Sensitive or Drug-Resistant Tuberculosis before and after Two Months of Therapy.

Authors:  Carl Nathan; Daniel W Fitzgerald; Kayvan Zainabadi; Kathleen Frances Walsh; Stalz Charles Vilbrun; Laurent Daniel Mathurin; Myung Hee Lee; Kohta Saito; Saurabh Mishra; Oksana Ocheretina; Jean William Pape
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.